PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 41,69 | 41,69 | 2026-03-27 |
| Vict Th Engwalls Stiftelse | 3,47 | 3,47 | 2026-03-27 |
| Arne Arvidsson | 1,82 | 1,82 | 2026-03-27 |
| Arne Skogvall | 1,73 | 1,73 | 2026-03-27 |
| Monica Billgert | 1,31 | 1,31 | 2026-03-27 |
| Nordnet Pensionsförsäkring | 1,21 | 1,21 | 2026-03-27 |
| Investment Aktiebolaget Balticum | 1,19 | 1,19 | 2026-03-27 |
| Tommy Johansson | 0,89 | 0,89 | 2026-03-27 |
| Fredrik Källström | 0,86 | 0,86 | 2026-03-27 |
| Avanza Pension | 0,86 | 0,86 | 2026-03-27 |
2026-05-21 Interim Report 2026-Q1
2026-08-20 Interim Report 2026-Q2
2026-11-19 Interim Report 2026-Q3
2027-02-18 Year End Report 2026
